Two-part Phase 1/2 study of OPK-88006, including an open-label SAD phase in healthy participants and a double-blind, randomized, placebo-controlled MAD phase in participants with presumed MASH, to evaluate safety, PK, and MASH related pharmacodynamic changes compared to placebo.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
30
OPKO study site
Miami, Florida, United States
RECRUITINGSAD - OPK-88006 maximum plasma concentration (Cmax)
To assess Cmax of OPK-88006 after a single dose
Time frame: 2 hours to 1 week
SAD - OPK-88006 Time to peak (Tmax)
To assess Tmax of OPK-88006 after a single dose
Time frame: 2 hours to 1 week
SAD - OPK-88006 Elimination half-life (T1/2)
To assess T1/2 of OPK-88006 after a single dose
Time frame: 10 hours to 200 hours
SAD - Frequency of treatment emergent adverse events (TEAE)
TEAEs will be graded as per National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Time frame: Up to 2 weeks
MAD - Frequency of treatment emergent adverse events (TEAE)
TEAEs will be graded as per National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Time frame: Up to 20 weeks
MAD - Change in body weight
Change from baseline in body weight (measured in kilograms) during the drug administration.
Time frame: Up to 17 weeks
MAD - Change in fasting lipids
Change from baseline in fasting lipid profile parameters
Time frame: Up to 17 weeks
MAD - Change in liver enzymes, alanine aminotransferase (ALT) and aspartate aminotransferase (AST)
Change from baseline in ALT and AST
Time frame: Up to 17 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
MAD - Change in liver stiffness with Vibration-controlled Transient Elastography (VCTE)
Change from baseline measured by VCTE
Time frame: Up to 17 weeks
MAD - Change in fibrosis markers measured by Enhanced Liver Fibrosis (ELF) score
Change from baseline in ELF score
Time frame: Up to 17 weeks
MAD - Change in hepatic fat measured by MRI-PDFF
Change from baseline in hepatic fat
Time frame: Up to 17 weeks